The SARS-CoV-2 virus has primed the global market for human pathogen detection in a historically unprecedented way. Post-pandemic, the appetite for affordable and accurate point-of-care pathogen testing will remain. In order to minimize the risk of pathogen-related shutdowns and disruption, routine screening of employees, contractors, and customers will need to become part of corporate health and safety culture.
CEOs need to satisfy their employees, underwriters, shareholders, customers, and suppliers by ensuring they have done everything possible to mitigate the business and safety risks posed by viruses and other pathogens.
Our tests are being developed specifically for corporate enterprises and other organizations that need to routinely screen large numbers of people for the purposes of maintaining workplace health and safety.